Q2 EPS Estimate for Keros Therapeutics Reduced by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at Wedbush reduced their Q2 2025 earnings per share (EPS) estimates for Keros Therapeutics in a report released on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($1.35) per share for the quarter, down from their previous forecast of ($1.27). Wedbush currently has a "Neutral" rating and a $15.00 target price on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($4.74) per share. Wedbush also issued estimates for Keros Therapeutics' Q3 2025 earnings at ($1.34) EPS, Q4 2025 earnings at ($1.32) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($5.32) EPS, FY2027 earnings at ($4.99) EPS, FY2028 earnings at ($4.18) EPS and FY2029 earnings at ($3.72) EPS.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $3.63. The business had revenue of $211.25 million during the quarter, compared to the consensus estimate of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the previous year, the firm earned ($1.21) earnings per share.

KROS has been the subject of a number of other reports. Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Oppenheimer dropped their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Scotiabank cut their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating for the company in a research note on Monday. HC Wainwright dropped their price objective on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald cut Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Keros Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $37.00.

Keros Therapeutics Stock Up 0.4%

NASDAQ:KROS traded up $0.06 on Friday, hitting $13.53. The stock had a trading volume of 347,387 shares, compared to its average volume of 824,567. The business's fifty day moving average is $12.27 and its 200 day moving average is $23.83. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $72.37. The company has a market cap of $549.52 million, a PE ratio of -2.60 and a beta of 1.32.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc bought 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the transaction, the insider now directly owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.90% of the company's stock.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors have recently bought and sold shares of the business. MetLife Investment Management LLC raised its position in shares of Keros Therapeutics by 6.0% during the fourth quarter. MetLife Investment Management LLC now owns 18,098 shares of the company's stock valued at $286,000 after buying an additional 1,027 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Keros Therapeutics by 11.3% in the fourth quarter. Handelsbanken Fonder AB now owns 10,800 shares of the company's stock valued at $171,000 after buying an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Keros Therapeutics by 19.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock valued at $136,000 after purchasing an additional 1,372 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Keros Therapeutics by 7.8% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,184 shares of the company's stock worth $303,000 after acquiring an additional 1,386 shares during the last quarter. Finally, Virtus ETF Advisers LLC lifted its position in Keros Therapeutics by 107.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after purchasing an additional 1,998 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.